Danske Bank A S Takes $116.41 Million Position in Abbott Laboratories $ABT

Danske Bank A S bought a new stake in Abbott Laboratories (NYSE:ABT) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 869,122 shares of the healthcare product maker’s stock, valued at approximately $116,410,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Stance Capital LLC boosted its stake in Abbott Laboratories by 4.8% in the third quarter. Stance Capital LLC now owns 10,048 shares of the healthcare product maker’s stock valued at $1,346,000 after acquiring an additional 461 shares in the last quarter. GM Advisory Group LLC increased its position in shares of Abbott Laboratories by 2.9% during the third quarter. GM Advisory Group LLC now owns 9,814 shares of the healthcare product maker’s stock worth $1,315,000 after purchasing an additional 273 shares in the last quarter. San Luis Wealth Advisors LLC purchased a new stake in shares of Abbott Laboratories in the 3rd quarter valued at about $603,000. Livforsakringsbolaget Skandia Omsesidigt boosted its position in shares of Abbott Laboratories by 1.0% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 49,936 shares of the healthcare product maker’s stock valued at $6,688,000 after purchasing an additional 500 shares during the period. Finally, OmniStar Financial Group Inc. acquired a new stake in shares of Abbott Laboratories in the 3rd quarter valued at about $1,173,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Up 0.8%

Abbott Laboratories stock opened at $110.80 on Wednesday. The stock has a 50 day moving average of $113.91 and a two-hundred day moving average of $123.50. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $139.06. The stock has a market capitalization of $192.98 billion, a price-to-earnings ratio of 29.79, a PEG ratio of 1.75 and a beta of 0.74. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the previous year, the company posted $1.34 earnings per share. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Insider Buying and Selling

In other news, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the sale, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. The trade was a 1.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Elizabeth C. Cushman sold 263 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $30,397.54. Following the transaction, the executive vice president owned 38,573 shares in the company, valued at approximately $4,458,267.34. This trade represents a 0.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have commented on ABT shares. Raymond James Financial cut their price target on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Evercore lowered their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Citigroup cut their target price on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a report on Wednesday, March 11th. Oppenheimer reduced their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Finally, Sanford C. Bernstein lowered their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $136.16.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.